Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

June 23, 2021

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Sung Won Lee, Jonggi Choi, Seung Up Kim, et al.

Clin Mol Hepatol. 2021;27(3):402-412.

Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short...

Review

December 3, 2020

Anti-fibrotic treatments for chronic liver diseases: The present and the future

Naoshi Odagiri, Tsutomu Matsubara, Misako Sato-Matsubara, et al.

Clin Mol Hepatol. 2021;27(3):413-424.

Liver fibrosis reflects tissue scarring in the liver due to the accumulation of excessive extracellular matrix in response to chronically persistent liver injury. Hepatocyte cell death can trigger capillarization of...

Review

December 3, 2020

β-blockers in advanced cirrhosis: More friend than enemy

Ki Tae Yoon, Hongqun Liu, Samuel S. Lee

Clin Mol Hepatol. 2021;27(3):425-436.

Nonselective beta-adrenergic blocker (NSBB) therapy for the prevention of initial and recurrent gastrointestinal bleeding in cirrhotic patients with gastroesophageal varices has been used for the past four decades. NSBB therapy...

Review

January 28, 2021

Changes in the epidemiology and management of bacterial infections in cirrhosis

Salvatore Piano, Marta Tonon, Paolo Angeli

Clin Mol Hepatol. 2021;27(3):437-445.

Patients with cirrhosis are susceptible to develop infections because of immune dysfunction, changes in microbiome and increase in bacterial translocation from the gut to systemic circulation. Bacterial infections can worse...

Original Article

February 2, 2021

Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry

Jong Man Kim, Deok Gie Kim, Jihyun Kim, et al.

Clin Mol Hepatol. 2021;27(3):451-462.

Background/Aims: To analyze the incidence and risk factors of outcomes after liver transplantation (LT) in the Korean population. Methods: This study analyzed data from the liver cohort of Korean Organ Transplantation...

Original Article

February 15, 2021

Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome

Han Ah Lee, Jihwan Lim, Hyung Joon Joo, et al.

Clin Mol Hepatol. 2021;27(3):463-473.

Background/Aims: Useful biomarkers for metabolic syndrome have been insufficient. We investigated the performance of serum milk fat globule-EGF factor-8 (MFG-E8), the key mediator of inflammatory pathway, in diagnosis of metabolic...

Original Article

February 19, 2021

The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients

Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, et al.

Clin Mol Hepatol. 2021;27(3):474-485.

Background/Aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on...

Original Article

February 23, 2021

Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort

Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, et al.

Clin Mol Hepatol. 2021;27(3):486-498.

Background/Aims: 17β-hydroxysteroid dehydrogenase 13 (HSD17B13) variants were recently reported to have significantly lower odds of non-alcoholic fatty liver disease (NAFLD). This is a two-part study that aimed to evaluate the...

Original Article

February 26, 2021

Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B

Lilian Yan Liang, Hye Won Lee, Vincent Wai-Sun Wong, et al.

Clin Mol Hepatol. 2021;27(3):499-509.

Background/Aims: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score...

Current Issue: Volume 27(3); Jul 2021

This archive contains links to the full-text of all issues of Clin Mol Hepatol.

Current issue

Volume 27(3); July

All issues

Vol. 27
2021

v.27(1)
Jan 2021

v.27(2)
Apr 2021

v.27(3)
Jul 2021

Vol. 26
2020

v.26(1)
Jan 2020

v.26(2)
Apr 2020

v.26(3)
Jul 2020

v.26(4)
Oct 2020

Vol. 25
2019

v.25(1)
Mar 2019

v.25(2)
Jun 2019

v.25(3)
Sep 2019

v.25(4)
Dec 2019

Vol. 24
2018

v.24(1)
Mar 2018

v.24(2)
Jun 2018

v.24(3)
Sep 2018

v.24(4)
Dec 2018

Vol. 23
2017

v.23(1)
Mar 2017

v.23(2)
Jun 2017

v.23(3)
Sep 2017

v.23(4)
Dec 2017

Vol. 22
2016

v.22(1)
Mar 2016

v.22(2)
Jun 2016

v.22(3)
Sep 2016

v.22(4)
Dec 2016

Vol. 21
2015

v.21(1)
Mar 2015

v.21(2)
Jun 2015

v.21(3)
Sep 2015

v.21(4)
Dec 2015

Vol. 20
2014

v.20(1)
Mar 2014

v.20(2)
Jun 2014

v.20(3)
Sep 2014

v.20(4)
Dec 2014

Vol. 19
2013

v.19(1)
Mar 2013

v.19(2)
Jun 2013

v.19(3)
Sep 2013

v.19(4)
Dec 2013

The Korean Journal of Hepatology1995 (Vol.1 No.1) to 2012 (Vol.18 No.1)

Vol. 18
2012

v.18(1)
Mar 2012

v.18(2)
Jun 2012

v.18(3)
Sep 2012

v.18(4)
Dec 2012

Vol. 17
2011

v.17(1)
Mar 2011

v.17(2)
Jun 2011

v.17(3)
Sep 2011

v.17(4)
Dec 2011

Vol. 16
2010

v.16(1)
Mar 2010

v.16(2)
Jun 2010

v.16(3)
Sep 2010

v.16(4)
Dec 2010

Vol. 15
2009

v.15(1)
Mar 2009

v.15(2)
Jun 2009

v.15(3)
Sep 2009

v.15(4)
Dec 2009

v.15(60)
Dec 2009

Vol. 14
2008

v.14(1)
Mar 2008

v.14(2)
Jun 2008

v.14(3)
Sep 2008

v.14(4)
Dec 2008

Vol. 13
2007

v.13(1)
Mar 2007

v.13(2)
Jun 2007

v.13(3)
Sep 2007

v.13(4)
Dec 2007

Vol. 12
2006

v.12(1)
Mar 2006

v.12(2)
Jun 2006

v.12(3)
Sep 2006

v.12(4)
Dec 2006

Vol. 11
2005

v.11(1)
Mar 2005

v.11(2)
Jun 2005

v.11(3)
Sep 2005

v.11(4)
Dec 2005

Vol. 10
2004

v.10(1)
Mar 2004

v.10(2)
Jun 2004

v.10(3)
Sep 2004

v.10(4)
Dec 2004

Vol. 9
2003

v.9(1)
Mar 2003

v.9(2)
Jun 2003

v.9(3)
Sep 2003

v.9(4)
Dec 2003

Vol. 8
2002

v.8(1)
Mar 2002

v.8(2)
Jun 2002

v.8(3)
Sep 2002

v.8(4)
Dec 2002

Vol. 7
2001

v.7(1)
Mar 2001

v.7(2)
Jun 2001

v.7(3)
Sep 2001

v.7(4)
Dec 2001

Vol. 6
2000

v.6(1)
Mar 2000

v.6(2)
Jun 2000

v.6(3)
Sep 2000

v.6(4)
Dec 2000

Vol. 5
1999

v.5(1)
Mar 1999

v.5(2)
Jun 1999

v.5(3)
Sep 1999

v.5(4)
Dec 1999

Vol. 4
1998

v.4(1)
Mar 1998

v.4(2)
Jun 1998

v.4(3)
Sep 1998

v.4(4)
Dec 1998

Vol. 3
1997

v.3(1)
Mar 1997

v.3(2)
Jun 1997

v.3(3)
Sep 1997

v.3(4)
Dec 1997

Vol. 2
1996

v.2(1)
Jun 1996

v.2(2)
Dec 1996

Vol. 1
1995

v.1(1)
Jun 1995

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

- Hepatocellular carcinoma statistics in South Korea

Viewed By 6152	Anti-fibrotic treatments for chronic liver diseases: The present and the future
Viewed By 2363	Programmed cell death in alcohol-associated liver disease
Viewed By 2322	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Viewed By 2266	Pathologic differential diagnosis of metastatic carcinoma in the liver
Viewed By 2036	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

Cited By 50	Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update
Cited By 40	KASL clinical practice guidelines for management of chronic hepatitis B
Cited By 28	Unmet need in chronic hepatitis B management
Cited By 24	Recent research trends and updates on nonalcoholic fatty liver disease
Cited By 19	Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?